Hemorrhagic Stroke Initiative
This ľ¹ÏÖ±²¥® initiative, sponsored by AstraZeneca, addresses the need for improved identification and treatment of hemorrhagic stroke patients.
The Hemorrhagic Stroke Initiative is evaluating new efforts to enhance the care of hemorrhagic stroke patients in hospitals and stroke centers across America.
Stroke is the No. 5 cause of death in the United States and a leading cause of disability. Hemorrhagic strokes make up roughly 10 percent of the nearly 800,000 strokes that occur annually, and they have a higher mortality rate than other types of stroke. Hemorrhagic stroke patients who are treated with novel oral anticoagulants, or NOACs, have an in-hospital mortality rate of 26.5%.
Recognizing Early Adopters
View Early Adopters
Built on the foundation of Get With The Guidelines®
See below for the 2022 Guideline Update regarding Intracerebral Hemorrhage. For professional education regarding this guideline, we've assembled a supporting presentation for internal hospital use.
Resources, Webinars & Podcasts
Stay up-to-date with the ľ¹ÏÖ±²¥'s Hemorrhagic Stroke Initiative. We will be posting webinars, podcasts, pathways & protocols, and other resources as they become available over the coming months. We also invite you to join our mailing list below to get even more information.
Contact Us
Looking for more information or details? Reach out with questions.